Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NGL-1 (Netrin-G1 ligand), also known as LRRC4C, is a transmembrane protein belonging to the leucine-rich repeat (LRR) family that serves as a key synaptic adhesion molecule [UniProt, https://www.uniprot.org/uniprotkb/Q969U0/entry]. It is primarily recognized for its role in the central nervous system, where it acts as a postsynaptic receptor for the presynaptic ligand Netrin-G1 to promote the development and maintenance of excitatory synapses [PubMed, https://pubmed.ncbi.nlm.nih.gov/14595443/]. Beyond its neurobiological functions, NGL-1 has been identified as a critical player in the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102144/]. In this context, NGL-1 is expressed by cancer-associated fibroblasts and immune cells, contributing to an immunosuppressive environment and supporting tumor growth through metabolic and signaling pathways [AACR, https://aacrjournals.org/cancerres/article/82/22_Supplement/PR017/710685/Abstract-PR017-Stromal-Netrin-G1-ligand-NGL-1-A]. Research indicates that disrupting the NGL-1/Netrin-G1 axis using experimental peptides can reduce tumor progression and improve response to chemotherapy, making it a promising target for cancer immunotherapy [bioRxiv, https://www.biorxiv.org/content/10.1101/2024.05.15.594354v1]. However, because of its essential role in brain function, therapeutic interventions must carefully consider potential neurological side effects, such as those observed in neurodevelopmental disorders like autism and schizophrenia [PubMed, https://pubmed.ncbi.nlm.nih.gov/31649508/].
Antagonism of the Netrin-G1/NGL-1 interaction to modulate the tumor microenvironment and restore anti-tumor immune activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat-containing protein 4C (NGL-1) (NGL-1).